Search

Ferric subsulfate

It has the chemical formula Fe4(OH)2(SO4)5. It is used after superficial skin biopsies.

Bimoclomol

Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

Androstenedione

Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.

Gedatolisib

Celcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.

Diacerein

Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is und...

Spinosad

Spinosad has also been experimented for use in cats for treatment of flea infestations, and has also been experimented for use against the KS1 Ctenocephalides felis flea strain infesting dogs, in addition

mRNA-1345

mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.

Ferric derisomaltose

Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.

Valoctocogene roxaparvovec

[A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807] … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States.

Polyinosinic-polycytidylic acid